title: Recommendation of the Advisory Committee on Immunization Practices (ACIP) for use of quadrivalent meningococcal conjugate vaccine (MenACWY-D) among children aged 9 through 23 months at increased risk for invasive meningococcal disease.
abstract: In April 2011, the Food and Drug Administration approved the use of a quadrivalent meningococcal conjugate vaccine (MenACWY-D) (Menactra, Sanofi Pasteur) as a 2-dose primary series among children aged 9 through 23 months. Vaccination with meningococcal polysaccharide vaccine (MPSV4) is not recommended for children aged <2 years because of low immunogenicity and short duration of protection in this age group.
mesh_terms: D000917:Antibody Formation; D006801:Humans; D007115:Immunization Schedule; D007074:Immunoglobulin G / Q000276:immunology; D007223:Infant; D008589:Meningococcal Infections / Q000517:prevention & control*; D022401:Meningococcal Vaccines / Q000008:administration & dosage* / Q000276:immunology; D012307:Risk Factors
chemical_list: D007074:Immunoglobulin G; C568160:MenACWY-D vaccine; D022401:Meningococcal Vaccines